SMARCA2 and cancer: Because BRM and BRG1 are frequently mutated in cancer3, we investigated if cancer cell lines with SWI/SNF mutations showed low GTF2H1 protein levels, as these cells would then likely be more susceptible to DNA damaging chemotherapeutic drugs.